Jan Bolinder

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

Jan Bolinder föddes 1952 i Västerås, tog läkarexamen vid Karolinska Institutet 1977 och disputerade där 1983. Samma år blev han specialist i allmän internmedicin och 1992 även i endokrinologi och diabetologi.

Åren 1983-85 innehade han en MFR/VR-finansierad forskartjänst på heltid och 1998-2004 på halvtid i klinisk diabetesforskning. Han blev 1985 docent vid Karolinska Institutet, och 1988 först biträdande överläkare därefter 1993 överläkare vid Centrum för metabolism och endokrinologi, Huddinge Universitetssjukhus.

Åren 1995-2003 var han sektionschef och områdesansvarig för diabetesvården vid kliniken, 2003 även tf verksamhetschef. Han är sedan 2004 prefekt vid institutionen för medicin, Karolinska Universitetssjukhuset, Huddinge.

Forskningsbeskrivning

Diabetes är en av våra stora folksjukdomar där framförallt den dramatiska ökningen av typ 2-diabetes, så kallad åldersdiabetes, utgör ett globalt hot mot folkhälsan.

Med mikrodialysteknik studerar forskargruppen hur frisättningen av fettsyror regleras i fettväv och muskelvävnad, och vilken betydelse detta har för utvecklingen av insulinresistens och typ 2-diabetes.

I olika samarbetsprojekt och kliniska studier studeras diabetesterapier och tekniker för kontinuerlig glukosmätning. Förekomst av diabetes och diabeteskomplikationer studeras av Diabetes Incidence Study in Sweden (DISS).

Artiklar

Article: DIABETOLOGIA. 2026;69(1):50-58
Uric acid and future complications in young individuals with type 1 diabetes: results from the Diabetes Incidence Study in Sweden (DISS) and the National Diabetes Registry of Sweden (NDR)
Fagher K; Eeg-Olofsson K; Arnqvist H; Bolinder J; Eriksson JW; Gudbjornsdottir S; Nystrom L; Landin-Olsson M
Article: DIABETOLOGIA. 2025;68(8):1647-1656
Severe hypoglycaemia is associated with increased risk of adverse cardiovascular complications in adults with type 1 diabetes: risk mitigation using intermittently scanned continuous glucose monitoring
Eeg-Olofsson K; Nathanson D; Spelman T; Kyhlstedt M; Seibold A; Levrat-Guillen F; Bolinder J
Article: JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY. 2025;19(1):143-152
Treatment Satisfaction and Well-Being With CGM in People With T1D: An Analysis Based on the GOLD Randomized Trial
Pylov D; Polonsky W; Imberg H; Holmer H; Hellman J; Wijkman M; Bolinder J; Heisse T; Dahlqvist S; Nystrom T; Schwarz E; Hirsch I; Lind M
Article: DIABETOLOGIA. 2025;68(1):41-51
Intermittently scanned continuous glucose monitoring compared with blood glucose monitoring is associated with lower HbA_1c and a reduced risk of hospitalisation for diabetes-related complications in adults with type 2 diabetes on insulin therapies
Nathanson D; Eeg-Olofsson K; Spelman T; Buelow E; Kyhlstedt M; Levrat-Guillen F; Bolinder J
Article: DIABETES CARE. 2024;47(12):2164-2171
Initiation of Intermittently Scanned Continuous Glucose Monitoring Is Associated With Reduced Hospitalization for Acute Diabetes Events and Cardiovascular Complications in Adults With Type 1 Diabetes
Eeg-Olofsson K; Nathanson D; Spelman T; Kyhlstedt M; Bulow E; Levrat-Guillen F; Bolinder J
Article: DIABETOLOGIA. 2024;67(8):1517-1526
Discordance between mean glucose and time in range in relation to HbA_1c in individuals with type 1 diabetes: results from the GOLD and SILVER trials
Isaksson SS; Imberg H; Hirsch IB; Schwarcz E; Hellman J; Wijkman M; Bolinder J; Nystrom T; Holmer H; Hallstrom S; Olafsdottir AF; Pekkari S; Polonsky W; Lind M
Article: JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY. 2024;18(1):89-98
Evaluation of Effects of Continuous Glucose Monitoring on Physical Activity Habits and Blood Lipid Levels in Persons With Type 1 Diabetes Managed With Multiple Daily Insulin Injections: An Analysis Based on the GOLD Randomized Trial (GOLD 8)
Nystroem T; Schwarz E; Dahlqvist S; Wijkman M; Ekelund M; Holmer H; Bolinder J; Hellman J; Imberg H; Hirsch IB; Lind M
Article: DIABETES THERAPY. 2023;14(9):1563-1575
Fast-Acting Insulin Aspart in Patients with Type 1 Diabetes in Real-World Clinical Practice: A Noninterventional, Retrospective Chart and Database Study
Lind M; Catrina S-B; Ekberg NR; Gerward S; Halasa T; Hellman J; Hess D; Londahl M; Qvist V; Bolinder J
Article: DIABETES TECHNOLOGY & THERAPEUTICS. 2022;24(S1):S35-S57
New Insulins, Biosimilars, and Insulin Therapy
Danne T; Heinemann L; Bolinder J
Article: DIABETOLOGIA. 2021;64(7):1595-1603
Effect of flash glucose monitoring in adults with type 1 diabetes: a nationwide, longitudinal observational study of 14,372 flash users compared with 7691 glucose sensor naive controls
Nathanson D; Svensson A-M; Miftaraj M; Franzen S; Bolinder J; Eeg-Olofsson K
Article: DIABETES TECHNOLOGY & THERAPEUTICS. 2021;23(S2):S46-S68
New Insulins, Biosimilars, and Insulin Therapy
Danne T; Heinemann L; Bolinder J
Article: DIABETES OBESITY & METABOLISM. 2021;23(2):619-630
The majority of people with type 1 diabetes and multiple daily insulin injections benefit from using continuous glucose monitoring: An analysis based on the GOLD randomized trial (GOLD-5)
Olafsdottir AF; Bolinder J; Heise T; Polonsky W; Ekelund M; Wijkman M; Pivodic A; Ahlen E; Schwarcz E; Nystrom T; Hellman J; Hirsch IB; Lind M
Article: DIABETES CARE. 2021;44(1):141-149
Sustained Intensive Treatment and Long-term Effects on HbA_1c Reduction (SILVER Study) by CGM in People With Type 1 Diabetes Treated With MDI
Lind M; Olafsdottir AF; Hirsch IB; Bolinder J; Dahlqvist S; Pivodic A; Hellman J; Wijkman M; Schwarcz E; Albrektsson H; Heise T; Polonsky W
Article: DIABETES TECHNOLOGY & THERAPEUTICS. 2019;21(S1):S57-S78
New Insulins, Biosimilars, and Insulin Therapy
Danne T; Heinemann L; Bolinder J
Article: DIABETES TECHNOLOGY & THERAPEUTICS. 2018;20(4):274-284
A Randomized Clinical Trial of the Effect of Continuous Glucose Monitoring on Nocturnal Hypoglycemia, Daytime Hypoglycemia, Glycemic Variability, and Hypoglycemia Confidence in Persons with Type 1 Diabetes Treated with Multiple Daily Insulin Injections (GOLD-3)
Olafsdottir AF; Polonsky W; Bolinder J; Hirsch IB; Dahlqvist S; Wedel H; Nystrom T; Wijkman M; Schwarcz E; Hellman J; Heise T; Lind M
Article: DIABETIC MEDICINE. 2018;35(4):491-494
Could FreeStyle Libre sensor glucose data support decisions for safe driving?
Rayman G; Kroeger J; Bolinder J
Article: DIABETOLOGIA. 2018;61(3):539-550
Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial
Oskarsson P; Antuna R; Geelhoed-Duijvestijn P; Kroeger J; Weitgasser R; Bolinder J
Article: DIABETES TECHNOLOGY & THERAPEUTICS. 2018;20(S1):S55-S70
New Insulins, Biosimilars, and Insulin Therapy
Danne T; Heinemann L; Bolinder J
Article: DIABETES RESEARCH AND CLINICAL PRACTICE. 2017;133:21-29
Overweight, hyperglycemia and tobacco use are modifiable risk factors for onset of retinopathy 9 and 17 years after the diagnosis of diabetes - A retrospective observational nation-wide cohort study
Tyrberg M; Nystrom L; Arnqvist HJ; Bolinder J; Gudbjornsdottir S; Landin-Olsson M; Eriksson JW; Svensson MK
Article: DIABETES TECHNOLOGY & THERAPEUTICS. 2017;19(S1):S42-S58
New Insulins, Biosimilars, and Insulin Therapy
Danne T; Heinemann L; Bolinder J
Visa fler

Alla övriga publikationer

Editorial: NEW ENGLAND JOURNAL OF MEDICINE. 2022;387(10):937-938
CLOuDs Disperse - Top-Notch Glucose Control and Residual C-Peptide Secretion
Bolinder J
Published conference paper: DIABETES TECHNOLOGY & THERAPEUTICS. 2020;22(S1):S32-S46
New Insulins, Biosimilars, and Insulin Therapy
Danne T; Heinemann L; Bolinder J
Letter: DIABETOLOGIA. 2018;61(8):1879-1880
Flash glucose monitoring: objective, not self-referential, outcomes are needed. Reply to Warren RE [letter]
Bolinder J; Oskarsson P; Antuna R; Geelhoed-Duijvestijn P; Kroeger J; Weitgasser R
Letter: LANCET. 2017;389(10077):1396-1397
Cutaneous adverse events related to FreeStyle Libre device Reply
Bolinder J; Antuna R; Geelhoed-Duijvestijn P; Kroger J; Weitgasser R
Corrigendum: DIABETOLOGIA. 2006;49(6):1457
Excess mortality in incident cases of diabetes mellitus aged 15 to 34 years at diagnosis:: a population-based study (DISS) in Sweden (vol 49, pg 1131, 2006)
Waernbaum I; Blohmé G; Ötman J; Sundkvist G; Eriksson JW; Arnqvist HJ; Bolinder J; Nyström L
Corrigendum: DIABETOLOGIA. 2004;47(1):154
Evaluation of the new ADA and WHO criteria for classification of diabetes mellitus in young adult people (15-34 yrs) in the Diabetes Incidence Study in Sweden (DISS) (vol 46, pg 173, 2003)
Borg H; Arnqvist HJ; Björk E; Bolinder J; Eriksson JW; Nyström L; Jeppsson JO; Sundkvist G
Letter: DIABETOLOGIA. 2002;45(7):1043-1044
Autonomic neuropathy is associated with impaired pancreatic polypeptide and neuropeptide Y responses to insulin-induced hypoglycaemia in Type I diabetic patients
Bolinder J; Sjöberg S; Persson A; Ahrén B; Sundkvist G
Published conference paper: TRANSPLANTATION PROCEEDINGS. 2001;33(4):2535-2536
Experience with human islet transplantation in Sweden
Tibell A; Bolinder J; Hagström-Toft E; Tollemar J; Brendel M; Eckhard M; Brandhorst D; Bretzel RG; Korsgren O; Groth CG
Meeting abstract: TRANSPLANTATION. 1999;67(7):S223
Ten-year results with pancreatic transplantation:: Persistent normoglycemia and superior patient survival
Tydén G; Bolinder J; Brattström C; Groth CG
Letter: DIABETOLOGIA. 1998;41(12):1532-1533
Islet autoimmunity before and after pancreas transplantation in patients with Type I diabetes mellitus.
Sundkvist G; Tydén G; Karlsson FA; Bolinder J
Published conference paper: TRANSPLANTATION PROCEEDINGS. 1998;30(7):3413
Diabetic patients subjected to combined pancreas and kidney transplantation or kidney transplantation alone:: Outcome after 5 to 10 years
Groth CG; Bolinder J; Solders G; Brattström G; Tibell A; Tydén G
Published conference paper: TRANSPLANTATION PROCEEDINGS. 1998;30(2):634
Long-term metabolic control in recipients of segmental or whole-organ pancreatic grafts with enteric exocrine diversion and function beyond 5 years.
Tyden G; Bolinder J; Brattström C; Tibell A; Grott CG
Published conference paper: TRANSPLANTATION PROCEEDINGS. 1998;30(2):332
A 10 year prospective study of IDDM patients subjected to combined pancreas and kidney transplantation or kidney transplantation alone
Tydén G; Bolinder J; Solders G; Nakache R; Brattström C; Tibell A; Groth CG
Published conference paper: TRANSPLANTATION PROCEEDINGS. 1997;29(7):3124-3125
Early experience with a long-distance collaborative human islet transplant programme.
Tibell A; Brendel M; Wadström J; Brandhorst D; Brandhorst H; Eckhard M; Bolinder J; Bretzel RG; Groth CG
Published conference paper: TRANSPLANTATION PROCEEDINGS. 1997;29(7):3119
A 10-year prospective study of IDDM patients subjected to combined pancreas and kidney transplantation or kidney transplantation alone
Tyden G; Bolinder J; Solders G; Nakache R; Brattstrom C; Tibell A; Groth CG
Letter: DIABETES CARE. 1997;20(7):1209
Self-monitoring of blood glucose compared with continuous tissue glucose measurement - Response to Sternberg et al.
Bolinder J; HagstromToft E; Arner P
Editorial: DIABETES, NUTRITION AND METABOLISM - CLINICAL AND EXPERIMENTAL. 1996;9(1):33-50
Hypoglycaemia warning on the basis of intracorporal glucose monitoring
Fischer U; Bendtson I; Bolinder J; Reach G; Guy RH
Published conference paper: TRANSPLANTATION PROCEEDINGS. 1995;27(6):3029-3030
Metabolic control in recipients of segmental pancreatic grafts functioning beyond 8 years
Tibell A; Tyden G; Bolinder J; Larsson M; Groth CG
Other: DIABETES CARE. 1995;18(8):1183-1186
COMPARISON OF BEDTIME NPH OR PREPRANDIAL REGULAR INSULIN COMBINED WITH GLIBENCLAMIDE IN SECONDARY SULFONYLUREA FAILURE
LANDSTEDTHALLIN L; ADAMSON U; ARNER P; BOLINDER J; LINS PE
Other: INTERNATIONAL JOURNAL OF OBESITY. 1995;19(5):350-354
INFLUENCE OF LOCAL BLOOD-FLOW ON GLYCEROL LEVELS IN HUMAN ADIPOSE-TISSUE
ENOKSSON S; NORDENSTROM J; BOLINDER J; ARNER P

Om mig

Forskningsbeskrivning

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI